CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT04739774
- Locations
- 🇧🇪
SGS Life Sciences - Clinical Pharmacology Unit Antwerpen, Antwerp, Belgium
TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD
- Conditions
- COPD
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Registration Number
- NCT04671355
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 3435
- Registration Number
- NCT04636801
- Locations
- 🇺🇸
Chiesi Clinical Trial - Site 840402, Sheffield, Alabama, United States
🇺🇸Chiesi Clinical Trial - Site 840480, Northridge, California, United States
🇺🇸Chiesi Clinical Trial - Site 840487, Cutler Bay, Florida, United States
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 3980
- Registration Number
- NCT04636814
- Locations
- 🇦🇹
Chiesi Clinical Trial - Site 40503, Linz, Austria
🇦🇹Chiesi Clinical Trial - Site 40505, Wels, Austria
🇧🇦Chiesi Clinical Trial - Site 70553, Banja Luka, Bosnia and Herzegovina
Study on Patterns of Care in Mild Asthmatic Patients
- Conditions
- Asthma
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 981
- Registration Number
- NCT04598555
- Locations
- 🇩🇪
DE-008 Lungenarztpraxis Hellersdorf, Berlin, Germany
🇩🇪DE-005 Praxis für Pneumologie und Innere Medizin, Fürstenwalde, Germany
🇩🇪DE-003 Praxis Pneumologie und Allergologie Dr. Ginko, Bonn, Germany
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
- Conditions
- Fabry Disease
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Registration Number
- NCT04552691
- Locations
- 🇺🇸
University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸Central Coas Nephrology, Salinas, California, United States
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 22
- Registration Number
- NCT04502433
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇮🇹Chiesi site # 14, Bologna, Italy
🇬🇧Chiesi site #4, London, United Kingdom
ARCANGELO (itAlian pRospective Study on CANGrELOr)
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1005
- Registration Number
- NCT04471870
- Locations
- 🇮🇹
Policlinico San Matteo, Pavia, Italy
🇮🇹A.O.U. Riuniti, Ancona, Italy
🇮🇹Ospedale San Bassiano, Bassano del Grappa, Italy
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
- Conditions
- COPDCOPD Exacerbation
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 3433
- Registration Number
- NCT04320342
- Locations
- 🇧🇬
Chiesi Clinical Trial Site 100113, Ruse, Bulgaria
🇺🇸Chiesi Clinical Trial Site 840206, Montgomery, Alabama, United States
🇺🇸Chiesi Clinical Trial Site 840144, Westminster, California, United States
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
- Conditions
- Neonatal Opioid Withdrawal Syndrome
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 7
- Registration Number
- NCT04104646
- Locations
- 🇺🇸
Clinical site 015, Las Vegas, Nevada, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States